We are delighted to inform you that Prof. Frank Grosveld (from Erasmus MC, Rotterdam) has been awarded the Princess Lilian Foundation visiting professorship 2013-14 at KU Leuven. Frank Grosveld is a world-leading expert in transcription and chromatin regulation in cell differentiation and disease, and also had his research accompanied by frontline development of multiple genome-wide omicsapproaches. Frank Grosveld will stay for 1 week in Belgium (March 16-March 22, 2014) and talk to researchers of KU Leuven and other Belgian universities. In Leuven, the opening ceremony, encompassing a public lecture by Frank Grosveld, and followed by a reception takes place on Monday, March 17, 2014 from 16:00 onwards at KU Leuven, Campus Gasthuisberg. In addition, …

Harbour Antibodies Licenses H2L2 Mice to Pfizer Harbour Antibodies, the creator of transgenic mice to aid in the development of new human therapeutic antibodies, announced today that it has licensed its H2L2 mice, which can generate human monoclonal antibodies, to Pfizer Inc. Harbour Antibodies’ transgenic H2L2 mice enable biotechs, pharmaceutical companies and academic research labs to speed new drug development by generating human antibodies using traditional hybridoma technology.  Under the licensing agreement, Pfizer will have the option to use the mice in as many projects as they wish without disclosing the nature of the projects to Harbour. This licensing deal marks the third partnership for Harbour Antibodies. Previous deals have …

Harbour Antibodies BV Raises €2.5M ($3.3M) to Accelerate the Development of Monoclonal Antibody Therapies Names BJ Bormann as new CEO Rotterdam and Cambridge, Massachusetts – July 24, 2013 — Harbour Antibodies BV, the creator of transgenic mice to aid in the discovery of new human antibody-based therapies, has raised €2.5M ($3.3M) to continue R&D and commercialize its technologies.  The round was led by Atlas Venture.  With the funding, pharma executive BJ Bormann, Ph.D. has been named as CEO.  Bormann’s previous positions have included SVP of Business Development and Licensing at Boehringer Ingelheim and VP of Strategic Alliances at Pfizer.  Atlas Venture’s Peter Barrett will join the Board of Directors as …

ShangPharma and Harbour Antibodies Announce Licensing Agreement SHANGHAI, Sept. 13, 2012 /PRNewswire/ — ShangPharma Corporation (NYSE: SHP) (“ShangPharma” or the “Company”), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, and Harbour Antibodies (“Harbour”), a Dutch biotechnology company, today announced that they have entered into a collaborative licensing agreement under which ShangPharma will develop therapeutic antibody candidates for its customers using Harbour’s transgenic mouse-based fully human antibody development technology. Harbour will provide ShangPharma with human immunoglobulin-gene transgenic mice for use at the Company’s Shanghai facility, where researchers will provide fully human antibody development services to ShangPharma’s pharmaceutical clients. The Harbour transgenic mice licensed under the agreement produce H2L2 …